WaikatoLink spin-off company OBodies are enjoying continued development as they launch their new website. The launch of the website coincides with their recent announcement of the formation of a scientific advisory board. Both these advancements are important steps towards securing partnerships and early market collaborations for the development of the technology.
OBodies is developing high affinity proteins (HAP’s), which provide a range of advantages over antibody proteins currently available on the market. The smaller size, enhanced binding ability, reduced production cost, and unique patent position are key advantages. The website will be an important part of show-casing their merging technologies to an international audience.